Equalizing prognostic disparities in KRAS-mutated stage III NSCLC patients: addition of durvalumab to combined chemoradiotherapy improves survival
KRAS mutations are a negative prognostic factor after cCRT in stage III NSCLC, and the addition of durvalumab ameliorates the negative impact of harboring this mutation.
Authors
- Sukanya Raghavan (ORCID: https://orcid.org/0000-0002-8073-8210)
- Andreas Hallqvist (ORCID: https://orcid.org/0000-0002-3705-194X)
- Sama I. Sayin (ORCID: https://orcid.org/0000-0003-1993-3487)
- Henrik Fagman (ORCID: https://orcid.org/0000-0001-5853-6295)
- Levent M. Akyürek (ORCID: https://orcid.org/0000-0002-1968-6458)
- Volkan I. Sayin (ORCID: https://orcid.org/0000-0002-5225-8260)
- Clotilde Wiel (ORCID: https://orcid.org/0000-0001-7042-4990)
- Jan Nyman (ORCID: https://orcid.org/0000-0002-2314-5902)
- Ella Ä. Eklund (ORCID: https://orcid.org/0000-0002-7962-6836)
- Johan Isaksson (ORCID: https://orcid.org/0000-0001-5787-0072)
- Mathilda Orgard
- Delice Wallin
Institutions
- Sahlgrenska University Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108573
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04